This course will provide an overview of different types of acquired thrombocytopenia. It will help clinicians gain familiarity with the pathogenesis of acquired thrombocytopenias and be able to establish a differential diagnosis. Thrombocytopenia is among the most common reason for consultation with a hematologist for both in-patients and out-patients. There are different disorders which can cause a low platelet count and put a patient at risk for bleeding. The course will help clinicians to understand the differences among the different underlying disorders and how to appropriately manage impacted patients.
This program is sponsored by an unrestricted educational grant by: Dova Pharmaceutical
ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis (ISTH). The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this Live activity for a maximum of 4 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 4 hours of participation for continuing education for allied health professionals.
This activity is intended for physicians involved in the diagnosis and management of patients who have a low platelet count.
Participants who engage in this educational intervention will be able to:
- Comply with basic knowledge of platelet production and the mechanisms of thrombocytopenia
- Ensure the pathogenesis of acquired thrombocytopenia and be able to establish a differential diagnosis
- Access and review key concepts in the clinical and laboratory diagnosis of ITP, DITP and HIT
In accordance with the ACCME® Standards for Commercial Support Six, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
- Ishac Nazy
- Shinji Kunishima
- Isabelle Michaux
- Geoffrey Horlait
In accordance with the ACCME® Standards for Commercial Support Six, all in control of content must disclose any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
Name | Company | Role |
---|---|---|
Donald M. Arnold, MD MSc | Novartis, Amgen, UCB and Rigel | Researcher & Consultant |
Tamam Bakchoul, MD | Aspen GMbH Germany, CSL-Behring and Hämostase Update | Speaker |
Siraj Mithoowani | Pfizer | Educational support recipient |
Cindy Neunert | Sanofi-Genzyme | Consultant |
Yves Gruel | Aspen and LFB | Speaker/Consultant |
François Mullier, PharmD, PhD, SpLM | Stago, Werfen, Nodia, Sysmex, Bayer; Boehringer Ingelheim, Bristol Myers Squibb and Pfizer | Research/Speaker |
Claire Pouplard | Stago | Contractor |
Brian Curtis | Ionis Pharmaceuticals | Advisory Board Member |